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Abstract: 
 
Protein-protein interactions play a central role within numerous processes in the cell.  
The relevance of the processes in which this type of interactions are implicated make 
them responsible of many pathological situations.  In the last decade protein-protein 
interfaces have shown their potential as new drug targets, and combinatorial chemistry 
has been defined as an useful tool in this line.  This review gives a global vision of the 
actual situation of combinatorial chemistry, highlighting its applicability to high-
throughput drug discovery and giving some crucial examples of its contribution to find 
modulators of protein-protein interactions. 
 
Abbreviations: 
Acquired immunodeficiency syndrome (AIDS), conformationally restricted libraries 
(CRL), hightroughput methods of screening (HTS), human immunodeficiency virus 
type 1 (HIV-1), nuclear magnetic resonance (NMR), rabies virus Nucleoprotein (N), 
rabies virus Phosphoprotein (P), structure activity relationship (SAR). 
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PROTEIN-PROTEIN INTERACTIONS AS DRUG TARGETS. 
The most generalised approach used to develop new therapeutic agents has been 
mostly based on the choice of a single gene product of clinical relevance as target. 
However, as it was early postulated and more recently experimentally confirmed, a 
large number of proteins inside the cell rarely stays alone.  Molecular signalling and 
signal transduction pathways at cellular level require massive protein usage in order to 
transmit signals through protein-protein interactions producing cell-answerings in 
response to different environmental changes or modifications.  Not only proteins in 
cellular pathways are busy seeking for interactions but structural proteins are also 
forming part of macromolecular structures and enzymes have regulatory and 
catalytically active subunits.  In this crowded scenario, in which protein-protein 
interactions are the main actors, it is reasonable to speculate that the modulation of 
protein-protein interactions could open new alternatives to the development of 
molecules that could modulate cellular pathways that in turn could have relevant future 
therapeutic applications.  Special attention is devoted to the drawing of the protein 
interaction maps.  In fact, there are now available cellular-protein interaction maps of 
model organisms[1], human[2,3], and some cellular pathways and, in addition, many 
genomes have been completely sequenced (see http://www.ensembl.org).  However, 
these maps represent only a very partial picture of the complete set of real interactions.  
Because detecting and analysing all protein-protein interactions by classical 
experimental methods is not as fast as genome sequencing, there is an unbalance 
between our knowledge on the basic pieces of the puzzle (the proteins) and the higher 
order relationships between them.  Thus, it would be useful for the identification of new 
potential targets the use of predictive bioinformatics methods based on different types 
of evidences such as sequence features [4] or different indirect experimental evidences 
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such as co-expression [5], domain-domain co-occurrence [6] and others methods.  
These approaches are becoming more and more accurate and now it is reasonable to 
take them as a starting point in absence of previous experimental evidence.  In addition, 
systematic whole-cell mass spectrometry approaches are currently used to identify 
protein complexes [7,8], which includes strong, transient and weak interactions between 
proteins that will increase our knowledge of interacting networks [9,10].  Nevertheless, 
data derived from all these methodologies clearly point to the need of taking into 
consideration protein-protein interactions as targets for the development of new drugs.  
In fact a study of the pairwise interactions among 8100 human open reading frames 
(that represents only about 10% of the total protein-coding genes), showed that at least 
in 424 of them one of the partners is implicated in human diseases [3] . 
 
Figure 1 
 
The development of modulators for protein-protein interactions is not exempt of 
difficulties.  Among others, one of the first identified problems is related to the nature of 
the surfaces that define these interactions.  While the ‘classical’ protein sites targeted by 
drug discovery programs are ligand binding sites, defined by small-concave 
cartographic spots, the protein-protein interaction surfaces are flat and large.  An 
extensive network of weak molecular interactions maintains the structure of the 
complex, then at a first glance, they were classified as extremely difficult target for 
small-molecules, that in turn were the favourite choice for drugs.  Years of investigation 
are now providing information on the detailed nature of these interactions that for sure 
will provide the hints to afford disruption of this type of complexes.  For example, now 
we know that the packing between molecules is not as tight as the core packing of 
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proteins, probably due to the less hydrophobic interaction surfaces and the presence of 
interfacial water molecules [11].  This flexibility allows multiple forms of protein-
protein complexes that can be initially classified as permanent, with no individual 
components found in the cell during protein lifetime and, transient complexes that are 
formed and disrupted in response to different cell situations.  The total extension of the 
interactive surface, considered a key parameter of the discovery strategy, would then 
probably vary when facing a small (close to 1000 Å2) or a middle to large (> 4000 Å2) 
interacting interface [11].  In addition, it is  well established now that when comparing 
the folding of an individual protein versus the structural arrangements needed for a 
protein-protein interaction there are differences on the role of the structural elements.  A 
correct ‘hydrophobic-driven’ single protein packing tends to collect hydrophobic 
elements of secondary structure inside the protein core regardless of their secondary 
structure.  However, it has been observed that in protein-protein interaction surfaces 
there is a ranking of preferences on packing, from high to low, between β-sheet/β-sheet, 
loop/loop, α-helix/α-helix while α-helix/β-sheet interactions are less favoured [11].  
Furthermore, statistical data also suggests that some defined amino acids have tendency 
to be more present than others at the protein-protein interfaces.  Methionine, tryptophan, 
cysteine, phenylalanine, tyrosine, arginine and histidine are overrepresented at transient 
molecular interfaces opposed to hydrophobic residues that are in general 
underrepresented in this type of surfaces [12].  Some amino acid pairs are frequently 
found in association like tryptophan and proline or phenylalanine and isoleucine.  It 
should be also noted that exposed hydrophobic interfaces tend to be small and although 
hydrophobic residues contribute to the binding affinity, these types of interactions are 
less specific than those composed of polar or charged residues. 
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Taking all this information together it seems that there is an infinite diversity in the 
universe of protein-protein interactions difficult to cope with from the point of view of 
the design of new therapeutics.  Nevertheless proteins are often constructed of modular 
domains that are used repeatedly in distinct molecules to mediate their interactions [13].  
For example, proline rich motifs are recognized by conserved interaction modules such 
as SH3, WW and EVH1 domains or phosphotyrosine motifs are recognized by SH2 or 
PTB domains.  These common features facilitate the development of general strategies 
for the inhibition of different molecular targets, which share an interaction motif 
although their cellular function could be completely different.  
In any case the remaining question is whether or not relatively small molecules, a 
desirable characteristic to consider a molecule as a potential drug candidate, could or 
not be capable of disrupting protein-protein interaction surfaces.  Recent progress in the 
field has provided a large number of examples [14,15] in which this strategy of 
modulation has prospered opening a new field for drug discovery.  Relevant and 
difficult to target diseases such as acquired immunodeficiency syndrome (AIDS), 
Alzheimer or cancer are being favoured with recent discoveries from methodologies 
using this strategy. 
A second key question is related to the methodological strategy that could be used to 
ensure the identification of active compounds able to inhibit these protein-protein 
interactions.  Is it necessary to use traditional searching or it is maybe better to use a 
combinatorial approach?.  The limiting factor for rational design is the requirement of 
an exhaustive knowledge of the targets in order to identify ‘hot spots’ along the 
interaction surface of proteins where small drugs could disrupt the complexes.  
Unfortunately, our current knowledge about protein-protein surfaces, even with enough 
structural data available, is extremely limited to permit the use of this rational strategy 
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as a general approach to modulate interactions.  Moreover in this new technological era 
where the information about protein interactions emerge as global interactome maps [3] 
in which thousands of proteins are inter-connected, it seems necessary to find a global 
strategy to perform the search of modulators for all these interactions.  It is in these 
situations where combinatorial approaches could be extremely beneficial and profitable, 
offering a great diversity of compounds to test protein-protein disruption activity and 
therefore overcoming the problem of lack of information.  From the technological point 
of view the use of combinatorial chemistry requires the development of hightroughput 
methods of screening (HTS) for protein-protein interactions in order to increase the 
probability of finding a lead compound.  There are many techniques available to 
identify protein partners such as yeast two hybrid system, mass spectrometry, protein 
chips (reviewed in [16]), POSSYCCAT for the study of interactions between 
transmembrane fragments [17], etc.  Once an active product has been identified, deeper 
studies could permit the location of the interaction site with its target and give the 
necessary information to improve the drug-protein interaction surface.  This site could 
probably be considered as a ‘hot spot’ on the interaction surface between the proteins.  
Furthermore, the discovery of a new inhibitor could facilitate the identification of the 
cellular processes in which this interaction is implicated.  In the cases where enough 
information about the target is available to initiate an adequate drug rational design, 
combinatorial chemistry could also contribute offering the possibility of improving its 
inhibition capabilities through structural modifications of the defined lead compound 
[18,19].  
This review will try to illustrate in a first stage the principles and types of 
combinatorial chemistry and how with this combinatorial approach it is possible to 
identify inhibitors for key protein-protein interactions. 
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COMBINATORIAL CHEMISTRY: A VALID APPROACH FOR TARGET 
VALIDATION AND DRUG DISCOVERY 
Combinatorial vs. traditional chemistry. Principles of combinatorial chemistry 
Traditionally, natural product extracts or industrial collections of randomly 
synthesised organic molecules (synthesised one at a time) were screened to discover 
“hits”, which were then optimised in an iterative process by the synthesis of 
derivatives.  Many important drugs were identified following this approach however 
the ratio of novel to previously discovered compounds started to diminish with time.  
This fact together with the cost constraints found on pharmaceutical research forced 
the investigation of methods in the pharmaceutical industry that could offer higher 
productivity at lower expenses.  By that time, genomics and proteomics had 
experienced an exponential growth and more potent and efficient technological devices 
for biological screening had also been achieved.  Altogether, triggered the appearance 
of a new discipline in the early 1980s: Combinatorial Chemistry [20].  
Combinatorial chemistry could be defined as “the generation of large collections, 
or ‘libraries’, of compounds by synthesising all possible combinations of a set of 
smaller chemical structures, or ‘building blocks’, in a time and submitted for 
pharmacological assay” [19-28].  In this way, the chemist can synthesise up to 
thousands of compounds at once instead of preparing only a few by simple 
methodology.  The traditional approach of organic synthesis to sequentially synthesise 
a logically designed set of analogues based on a lead compound has been surpassed by 
the ability to screen whole compound libraries accumulated over the years by large 
pharmaceutical companies.  Therefore, with the combinatorial strategy the productivity 
has been amplified beyond the levels obtained as routine in the last century [29,30]. 
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Solid-phase and solution-phase combinatorial chemistry 
Solid phase peptide synthesis methodology, introduced by Merrifield in 1963, 
paved the way for solid-phase combinatorial approaches (extensively reviewed in 
[27,28,31-35]).  Geysen [36,37] was the pioneer in this field synthesising peptides on 
pin-shaped solid supports followed by Houghten with his “teabag” approach to epitope 
mapping [38].  Solid-phase combinatorial chemistry has been widely implemented for 
hit discovery as well as lead optimisation due to its advantages and simplicity of use, 
advantages such as: (i) the compounds can be isolated once they are attached to solid 
supports, (ii) the isolation of the immobilised product by simple filtration permits the 
use of large reagent excesses to get high-yield conversions for each of the steps, (iii) 
pseudo-dilution effects are present and (iv) the use of split-and-mix synthesis 
simplifies the preparation of large libraries [15].  
The split-and-mix solid–phase synthesis on beads was introduced by Furka et 
al.[39,40].  This technique has been enthusiastically exploited by many others since its 
first disclosure.  For example, Houghten has used split-and-mix on a macro scale in a 
"teabag" approach for the generation of large libraries of peptides [41].  Lam et al. [42-
44] was able to enhance the production and rapid evaluation of random libraries of 
millions of peptides in a way that acceptor-binding ligands of high affinity could be 
rapidly identified and sequenced, on the basis of a 'one-bead, one-peptide' approach.  
Consequently to the large acceptance achieved by the split-and-mix strategy, several 
identification techniques have been also developed, such as nucleotide- [45,46], 
peptide- [47,48], chemical- [49], radiofrecuency- [50], color- [51], and shape- [52-54] 
encoded or iterative [55-57] and recursive [58,59] deconvolution. 
Unfortunately, there is not an ideal general technique, therefore, among the 
limitations of solid-phase combinatorial synthesis should be mentioned the restriction 
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of being only suitable in linear synthetic strategies and the requirements for linkage or 
cleavage steps that may restrict the possible chemical reactions.  A hydroxyl, amine, 
carboxyl, or other polar group must be present on a molecule to be able to attach it to a 
support.  This is a potentially undesirable constraint on the structure of compounds 
synthesised on solid phase, as products retain the polar group even after they are 
cleaved from the support.  Several groups have been devoted to diminish these 
drawbacks in order to continue improving the implementation of solid-phase synthesis.  
The use of ‘Traceless linkers’ [12,60-62] have been one of the most remarkable 
implementations.  For instance, Mori and coworkers [60,63] have developed an aniline 
linker for solid-phase synthesis of azomethines or Ellman et al. [64] have reported an 
acylsulfonamide linker able to add diversity to a library when displaced by various 
nucleophiles at the same time that is completely removed from products during the 
cleavage process.  Furthermore, other innovative techniques for solid-phase synthesis 
have been developed, including: react-and-release type chemistry [65], in which 
reagents used to cleave products from the solid support are incorporated into the 
product; use of scavenger resins [66]; the introduction of safety-catch linkers [67-69] 
or the improvement of resin properties and loading capacities [70-72].  
Although the solid-phase combinatorial chemistry is still the most widely used, 
several groups have been applying an alternative solution-phase approach to 
complement solid-phase techniques.  Solution-phase synthesis offers the possibility of 
expanding the repertoire of chemical reactions and allows the application of 
convergent synthetic strategies, the synthesis of mixture libraries or the use of dynamic 
libraries [73,74].  
Dynamic combinatorial chemistry [29,73,74] is based on continuous 
interconversion between the library constituents, it uses reversible connections 
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between the initial building blocks producing flexible and adaptive libraries.  This 
approach is driven by the interactions of the library constituents with the target site.  
This strategy allows a target-driven generation or amplification of active constituents 
by performing a self-screening process where the active species are preferentially 
expressed and retrieved from the library [73].  A similar concept is found in Phage 
displayed libraries (biologically displayed libraries) [75-77] first published on 1985 by 
Smith et al.[78].  These offer a strategy to isolate peptide ligands to target proteins and 
to define interaction sites between proteins [79].  In phage displayed libraries, instead 
of using inter-convertible building blocks as it is done in dynamic libraries, possible 
active peptides or oligonucleotides (phage population) are screened by incubation with 
the target molecule adsorbed to a solid support.  Active phages bind the target, then 
target-bound phages are isolated and propagated by infection of E. coli and subjected 
to an additional round of adsorption to the immobilised target.  The use of biological 
displayed libraries for the isolation of peptide ligands is an interesting alternative to 
chemical libraries. 
Both, solid-phase and solution-phase strategies can be easily automated, however, 
the major limitation to solution-phase is the isolation and purification of the library 
compounds [80,81].  To date, most of the isolation/purification steps are based on acid-
base chemistry and sequestration-enabling reagents [82-84].  The pioneering acid-base 
extraction approach of Boger et al. [85], clearly showed the possibility of generate 
large libraries of pure molecules.  His work has been mainly focused on the main 
concept raised in this review, the discovery of small compounds (mainly 
peptidomimetics) inhibitors of protein-protein interactions [15].  Mixture synthesis 
provides for solution-phase synthesis what split-and-mix synthesis provides for solid-
phase approaches (reviewed in [86,87]). 
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Analogous to encoding approaches for split-and-mix synthesis of large libraries 
(also known as iterative approach), there are two key and complementary 
deconvolution strategies that permit the immediate identification of active lead 
compounds from large mixture libraries: positional scanning[88,89] and deletion 
synthesis [90,91] techniques.  The positional scanning approach was first described by 
Houghten et al. [88,89] and was developed as an alternative to the iterative strategy 
where the lead identification was achieved through successive steps of mixture 
selection with the active compound, synthesis of sublibrary and subsequent evaluation, 
that is, only one residue can be identified at a time by a synthesis-assay cycle.  When 
using a positional scanning approach [92,93] several sublibraries can be synthesised at 
a time, in each sublibrary an individual component is placed in one position but 
mixtures are used in all others.  The most active sublibrary in each set indicates the 
optimal substituent for that position so, an increase in activity is measured that allows 
the identification of active lead structures.  On the other hand, in deletion synthesis 
deconvolution libraries [90], an individual component is missing in each sublibrary but 
full mixtures are used in all other positions.  The least active sublibrary in each set 
indicates the optimal substituent for that position as the missing component that in 
turn, will be the most active.  This strategy provides less global information that 
positional-scanning but is better at identifying a uniquely potent library member.  It is 
important to note that, with either of both techniques, the lead identification comes out 
from a single round of screening. 
 
SUITABILITY OF COMBINATORIAL APPROACH TO TARGET PROTEIN-
PROTEIN INTERACTIONS 
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Despite the already described inherent difficulties in the process to identify small 
compounds modulators of protein-protein interactions, there are several important 
modulators of this type of complexes that have been defined using combinatorial 
approaches.  Some of the more representative examples are described in more detail 
below (Table 1). 
 
Apoptosis inhibitors 
Programmed cell death or apoptosis is a highly regulated process of cell deletion 
that plays crucial roles in development and maintenance of tissue homeostasis in 
multicellular organisms.  Due to the relevance of this cellular mechanism its 
deregulation is a key issue in the pathogenesis of several human diseases such as cancer 
or neurodegenerative disorders [94].  This type of cellular death can be triggered by a 
variety of extrinsic and intrinsic signals [95]. 
 
Inhibitors of apoptosome formation. 
In the apoptosis pathway in mammals the formation of a multiprotein complex 
called apoptosome between cytochrome c, Apaf-1 (apoptotic protease-activating factor) 
and procaspase-9 links mitochondria dysfunction with the activation of the effector 
caspases starting the cascade of cell death [8,96-98].  Our laboratory focused on the 
identification of compounds that inhibit the apoptosome-mediated activation of 
procaspase-9 from the screening of a positional scanning diversity-oriented 
combinatorial library of trimers of N-alkylglycines [99].  These type of molecules also 
known as peptoids present a series of characteristics that make them good candidates to 
cope with the disruption of protein-protein interactions.  Its main chain is quite similar 
to a polypeptide but with the lateral side chain on the nitrogen atom instead of the 
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carbon thus giving the advantage of the similarity at the same time that conferring 
flexibility to the scaffold which could favour the interaction with the target surface 
[100].  Moreover, due to this chemical difference with proteins, cellular proteases are 
not able to degrade this type of substrates increasing the lifetime of the drug inside the 
organism.  The library consisted in 52 controlled mixtures and a total of 5120 
compounds.  Mixtures 1 to 20 (O1XX) contain as defined position one of 20 selected 
commercially available primary amines, while at the ‘X’ positions (mixture positions) a 
set of 16 primary amines was present.  Mixtures 21 to 36 (XO2X) and 37 to 52 (XXO3) 
contain at the defined position only a set of 16 amines.  The mixtures making up each 
sublibrary were screened for their ability to prevent the apoptosome-dependent 
activation of procaspase-9.  For this goal the apoptosome was assembled in vitro by 
incubating rApaf-1, cytochrome c, dATP and [35S]-Met procaspase-9. 
After the identification of a lead compound (peptoid 1) rescued from the library a 
rational strategy was used to improve its solubility as well as its cellular internalisation 
capability, obtaining finally a drug with antiapoptotic activity in different cell lines, see 
Fig (2). 
Figure 2 
 
Inhibitors of interaction between pro- and anti-apoptotic proteins. 
The response of mitochondria to apoptotic signals is a key point of regulation of 
apoptosis that is controlled by the Bcl-2 family of proteins.  In particular by the balance 
between pro- and anti-apoptotic proteins in the mitochondrial membrane.  Anti-
apoptotic Bcl-2 proteins (for example, Bcl-2 and Bcl-XL) are the target of pro-apoptotic 
proteins (like Bad, Bax, Bak) that through their BH3 domain bind to a hydrophobic cleft 
on the surface of Bcl-2 or Bcl-XL.  Several lines of evidence indicate that BH3-mediated 
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binding has a key role in regulating apoptotic functions.  In fact, short peptides derived 
from BH3 domains of various pro-apoptotic Bcl-2 family members are sufficient to 
induce apoptosis in cells [101].  To identify small-molecule inhibitors of Bcl-XL-BH3 
domain interaction, Degterev et al. [102] screened a commercially available library of 
16320 chemicals and found hit compounds that after chemical optimisation rendered 
biologically active compounds that inhibited the interaction between Bcl-XL and BH3 
domains and induced apoptosis in Jurkat cells.  The same protein-protein complex was 
selected as target by Oltersdorf et al. [103].  However in this study they applied the 
methodology of SAR by NMR.  In this methodology a library of small chemical 
fragments is screened against the protein target to identify low-affinity binding 
compounds.  Then the chemical linkage of proximal fragments would render a new 
molecule with high binding affinity to the target.  Using this technique a small 
molecule, named ABT-737, with high affinity (Ki< 1 nM) to Bcl-XL, was identified, see 
Fig (3).  ABT-737 displayed synergism with chemotherapeutics and radiation.  
Furthermore, the compound showed in vivo anti-tumor activity causing complete 
regression of established tumor xenografts. 
 
Figure 3 
 
Viral inhibitors 
Combinatorial libraries have also contributed to the inhibition of the life cycle of 
certain viruses such as the human immunodeficiency virus or the rabies virus. 
HIV protease dimerisation inhibitors 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus with a very complex 
life cycle in which at least 15 protein are implicated [104].  Several drugs targeting 
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different steps of this cycle have been developed.  One of the main pharmacological 
targets is the virus protease (PR), a pivotal enzyme in viral maturation responsible of 
processing the polyproteins encoded by the virus rendering active proteins needed for 
the assembly and the infection steps of the virus particle [105].  PR is an homodimeric 
aspartil protease with the active site located at the interface of the dimmer [106].  This 
dimerisation interface is a highly conserved region which makes it a relevant target for 
drug discovery.  The main dimerisation region is folded as an interdigitating N-and C-
terminal four stranded β-sheet.  The group of Chmielewski using rational design 
developed inhibitors of the PR dimerisation derived from crosslinked interfacial 
peptides corresponding to this conserved β-sheet region and identified the minimal 
structure necessary for the activity of these peptides [107].  Moreover in an attempt to 
improve its activity a focused library on the basis of this minimized molecule was 
designed (compound 6) in which certain side chains were substituted by different 
natural and non natural amino acid side chains, see Fig (4).  The analysis of the library 
not only gave information about the groups that confer better characteristics in each 
position but also rendered a molecule (compound 36, Fig (3)) with improved activity 
respect to the initial scaffold.  
Figure 4 
 
Rabies virus infection inhibition 
Infection by rabies virus is the cause of thousands of deaths by encephalomyelitis 
per year in the world.  The clear need to have a post-exposure treatment led the group of 
Yves Jacob to work on the development of a new virucidal drug [108].  Rabies virus is a 
member of the lyssaviruses family.  Among other viral constituents the Phosphoprotein 
(P) is crucial for the formation of the transcription-replication complex, in which 
 17
interacts with the RNA-polymerase and the nucleoprotein (N).  Moreover P also 
interacts in the cell with Dynein LC8 a protein implicated in retrograde transport.  These 
characteristics made P a good target to develop a new virucidal drug, although there was 
no structural information about the complexes in which it participates.   Ybes Jacob and 
coworkers designed two genetically encoded combinatorial peptide libraries, called 
coactamer libraries.  In these libraries the peptide scaffold is structurally constrained 
due to the presence of either prolines or cysteines.  This structure mimics conotoxins 
and insect antimicrobial peptides, which easily reach the cellular interior, in an attempt 
to increase drug bioavailability.  A two hybrid assay was used to identify peptides 
interacting with phosphoproteins from two different lyssaviruses.  Peptides selected 
from the library were tested for its viral transcription-replication complex interference 
activity.  To be sure that their activity were related with an alteration of the N-P 
interaction a ProteinChip with an anti-Flag M2 monoclonal antibody cross-linked was 
used to immunoprecipitate P and its associated proteins from cell extracts in the 
presence or absence of  the co-transfected inhibitor peptides.  Peaks corresponding to 
the interaction between P and N were analysed by SELDI-TOF, and four peptides 
modulators of the ratio P/N (indicator of an altered interaction) were identified. 
Table 1 
 
Inhibitors of cell migration 
Integrin αvβ3 / MMP-2 
Integrin αvβ3 is an heterodimeric cell surface receptor that promotes cell attachment 
to the extracellular matrix.  MMP-2 (gelatinase A) a protein secreted by vascular 
endothelial cells is crucial for the degradation of collagen matrix which permits new 
vessels to proliferate.  Moreover, the interaction between integrin αvβ3 and MMP-2 
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seems to be responsible for the activation of MMP-2 in invasive endothelial cells [109]. 
Disruption of this protein-protein interaction is one of therapeutic strategies that are 
being exploited for tumor growth inhibition.  Screening of a library composed of  ten 
mixtures of 60 small organic compounds designed to mimic potential protein–protein 
interactive moieties have led to the identification of a lead compound with in vitro 
activity.  Posterior refinement experiments permitted to obtain a more water-soluble 
molecule with antitumor and antiangiogenic in vivo activity [110].  One of the active 
compounds, termed TSRI265, was shown to prevent collagen IV degradation in hamster 
CS-1 melanoma cells transfected with the human 3-integrin, see Fig (3).  Furthermore, 
TSRI265 almost completely inhibited FGF-stimulated angiogenesis in 10-day-old 
chick chorioallantoic membrane.  The data obtained from this study set the basis to 
consider inhibition of MMP-2/ v 3 binding as a crucial molecular target to block the 
angiogenic process [111]. 
     
Integrin α4β1 / Paxillin 
The interaction between the signal adaptor protein Paxillin and the cytoplasmic tail 
of integrin α4β1, a cell surface receptor, has been implicated in several pathogenic 
situations including enhanced rates of cell migration, reduced rates of cell spreading, 
focal adhesion, and stress fibber formation [112].  All these processes contribute to 
leukocyte migration into tissues and to the expression of genes involved in chronic 
inflammation.  From the screening of a combinatorial library in an ELISA assay using 
immobilised His-tagged α4 and examining the binding of Paxillin, Boger and coworkers 
obtained a lead molecule that inhibits this interaction [92].  The library consisted of a 
scaffold composed of three different variable subunits (X,Y and Z) linked by amide 
bonds, and a basic side chain 4-(dimethylamino) butyric acid linked to the X subunit, 
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see Fig (5).  For each variable position ten aromatic amino acids were used.  The library 
was prepared in solution using two different formats, as 100 mixtures of 10 compounds 
and using a positional scanning approach in which 30 sublibraries were generated.  
Results using the two types of library formats were quite similar.  The lead molecule 
(11 X7-Y7-Z7 ), see Fig (3), obtained from the screening not only disrupted Paxillin/ 
Integrin α4β interaction but also demonstrated a potent inhibition activity of human 
Jurkat T cell migration. 
Figure 5 
 
Cell cycle inhibitors 
Cell growth in eukaryotic cells is under control of a series of concerted molecular 
mechanisms defined as the cell cycle.  In cell life cycle there are strict checkpoints 
controlling cells prepared to enter mitosis.  The p16-cyclinD-pRB-E2F pathway 
controls the G1/S transition of the mammalian cell cycle.  E2Fs are a family of  
transcription factors (E2F1 to E2F7 in mammalian cells) that require heterodimerization 
with proteins of the DP family to bind DNA and exert its regulatory function over genes 
implicated in DNA replication [113,114].  Activation of E2F dependent transcription 
promotes progression from G1 to S and conversely its inhibition arrests cells in G1 
[115].  Sardet and coworkers [116] identified, from the screening of a combinatorial 
library of thiorredoxin-20mer peptide (called aptamers), a molecule that interacts with 
E2F1 dimerization domain.  For this purpose, a two hybrid assay with E2F1 
dimerization domain as a bait, was used.  Among the molecules identified there was one 
peptide (Apt5) that shared notable sequence similarity with a region of DP1.  More 
extensive studies demonstrated that this molecule interferes with the interaction between 
E2F/DP.  Moreover, deeper studies in mammalian cells demonstrated that Apt5 is 
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capable of blocking fibroblasts in G1 reinforcing the hypothesis that this interaction 
could be considered as a key target for the development of pharmaceutical 
antiproliferative agents.  
 
Inhibitors of G-proteins  
Heterotrimeric G-proteins (Gαβγ) transform the signal produced by G-protein 
coupled receptors in an intracellular signal.  In humans the wide diversity of receptors 
together with the great number of isoforms of G-proteins generate a pool of complexes 
implicated in a wide variety of cellular processes ranging from neurotransmission or 
embryonic development [117] to respiratory control [118].  Drug discovery efforts that 
initially were directed to G-coupled receptors now have been focused in G-proteins and 
its intracellular partners. 
In an attempt of interfere with these interactions the group of Scott JK used different 
phage displayed peptide libraries (Table 1) that were screened against immobilized βγ 
subunits as target [119].  Selected peptides were grouped into different families and one 
of the groups identified was shown to share notable homology with peptides derived 
from Phospholipase C β2 (PLC β2).  These peptides in fact prevented activation of PLC 
β2 by Gβγ subunits but did no block Gβγ-mediated of voltage-gated calcium channels 
which remarks the pathway specificity of the molecules.  Moreover all peptides selected 
were predicted to bind to the same site of the Gβγ-subunits.  In this sense the screening 
of the library not only rendered active molecules but also gave information about a ‘hot 
spot’ site in Gβγ for binding interaction [120].  This information could be of great 
interest for the posterior refinement of the peptide/protein interactions as well as for the 
development of new pharmaceuticals using a traditional strategy. 
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Conformationally restricted libraries (CRL). 
The main characteristic of these libraries is that the random sequences (the 
diversity) are grafted onto a rigid natural protein domain or into stable secondary 
structural motifs usually named as the scaffold of the CRL [121,122].  The sequence of 
the scaffold is kept in its major part and only a few positions are combinatorialised.  
Hence, the library presents dual diversity, namely of sequences and structures.  An 
adequate selection of the combinatorialised positions in the scaffold allows the 
generation of molecules that virtually populate the conformational space between the 
random and the fully folded conformation which, in turn, depends on the selected 
scaffold.  The aims of the design of a monomeric α-helix CRL was based on its 
potential use as source for the identification of molecules that would modulate protein-
protein interactions.  In this context, the α-helical based CRL was screened in two 
different biological assays.  In particular, we were interested in the modulation of 
protein-protein interactions that mediate membrane fusion.  The mechanism of 
virus-cell fusion of some enveloped viruses and in particular for rhabdoviruses 
revealed that, to fuse with the cellular membranes, the G protein trimeric spikes find 
and bind to their target cells.  However, the molecular mechanisms involved in 
rhabdovirus fusion are not well understood and it might involve new proteins or 
principles yet to be discovered.  The screening of the library allowed the identification 
of peptides that enhanced the infectivity of rhabdoviruses [8,123].  These peptides are 
currently being used in studies addressed to understand the molecular mechanism that 
control the fusion of the rhabdovirus to the target cell.  In a different biological assay 
we addressed the identification of novel modulators of the SNARE complex as 
inhibitors of regulated exocytosis.  Calcium-dependent exocytosis in excitable cells is 
mediated by the precise docking and fusion of neurotransmitter-loaded cargo vesicles 
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[124,125].  Mechanistically, neuronal exocytosis is an orchestrated cascade of protein-
protein interactions that involve several proteins.  At the centre of the process are 
found the so-called SNARE proteins that assemble into a highly stable, ternary 
complex known as the SNARE core complex. [124-127].  Structurally, the SNARE 
complex is a highly stable parallel four helix bundle formed by coiled coil 
arrangements.  The high stability of the SNARE complex has hampered the discovery 
of small molecules that modulate the assembly of the proteins and only clostridial 
neurotoxins and peptides patterned after protein domains of SNARE proteins have 
been reported to have an effect on the assembly [128-130]. However, the discovery of 
amino acid sequences unrelated to the SNARE proteins capable to inhibit the assembly 
of the core complex remained elusive.  From the screening of the α-helix CRL we 
identified up to 8 peptides that inhibited in vitro the formation of the SDS resistant 
SNARE complex.  The most active 17-mer peptide abrogated the Ca2+-dependent 
release of L-glutamate in intact hippocampal neurons [130].  
 
Conclusion 
The network of protein interactions that defines the full interactome of proteins of 
cellular regulatory mechanisms is far broader than the subject matter reviewed here.  
Consequently, the identification of molecules that inhibit protein-protein interactions 
reviewed here should be viewed as a starting point upon which to build the concept 
that such protein-protein interactions are pharmacologically accessible by small 
molecules.  The actual and future molecules that will modulate interactions between 
proteins, not only would have the chance to be promote to ‘more promising hits to 
drugs’ but also will define valuable tools for the study of cell biology.  The use of 
collections of molecules or compound libraries together with the availability of 
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structural and bioinformatics information for key protein-protein complexes have 
significantly open new views to the understanding of how modulators of protein-
protein interaction could be developed.  In turn, these findings open important 
questions and perspectives that will be the driving force for future research.  Questions 
ahead will look upon the ‘strength’ of the interactions between proteins and how many 
transient interactions (difficult to identify in the cellular context) that are still 
undiscovered, will be classified as key points of regulation in cellular pathways.  
However, combinatorial chemistry in its different formats will be always a valuable 
and useful tool to face research programs for the identification of modulators of 
protein-protein interactions, specially when structural information of the complex is 
not available but a biological activity could be evaluated. 
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Tables 
 
Table 1.   Libraries and screening methods used in the different protein-protein 
interaction assays. 
 
PROTEIN-PROTEIN 
INTERFACE 
METHOD OF 
SCREENING 
TYPE OF 
LIBRARY REF. 
Apaf-1/apoptosome [S
35] Procaspase 9 
processing 
Trimers of N-
alkylglycines [99] 
Bcl-XL/BH3 Bak 
Fluorescence 
polarization assay 
16320 organic 
compounds [102] 
HIV-protease 
dimerization interface Enzymatic assay 
Focused library of 
interfacial peptides [107] 
Phosphoprotein/ 
nucleprotein from 
Rabies virus 
Yeast two hybrid assay Coactamer libraries 
[108] 
 
Integrin αvβ3/ MMP-2 Solid phase receptor-binding assays 
Mixtures of  small 
organic compounds [111] 
Paxillin/ integrin α4β1 
ELISA assay with 
immobilized His-tagged 
α4 
4-(dimethylamino) 
butyric acid-A-B-C [131] 
E2F/DP Yeast two hybrid assay Thioredoxin-20mer peptides (aptamers) [116] 
Gβγ 
Phage displayed 
libraries against 
immobilized βγ subunits
Linear Disufide-
bridged-loop Half –
Cys α-conotoxin 
[119] 
Rhabdovirus Trimeric 
G protein Virus infectivity α-helical CRL [123] 
Snare complex 
 
SDS-PAGE α-helical CRL [129] 
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Legend to figures 
 
Figure 1. Representative examples of solved strutures of known protein-protein 
interfaces. (A) CARD domain of Apaf-1/prodomain of caspase (3YGS) [132] (B) 
Dimeric HIV protease (1AID) [133]  (C) Integrin alpha2 I domain/collagen complex 
(1DZI) [134]  
Figure 2.  Apaf 1 inhibition by identified peptoids. (A) Structure of the lead compound 
obtained from the screening, peptoid 1, and a more soluble derivative peptoid 1a. (B) 
Apoptosome-dependent activation of procaspase-9 followed by incubating in vitro 
transcribed-translated [35S]-Met procaspase-9 and rApaf-1 in the presence cytochrome 
at different concentrations of peptoid 1a. (C) Structures peptoid 1 third generation 
derivatives:  penetratin-GG-peptoid 1, cyclo-peptoid 1a and PGA-GG-peptoid 1. 
Figure   3.  Structure of active compounds obtained from the screening of different 
libraries in protein-protein interaction assays. 
Figure 4. Structure of the focused library designed to inhibit HIV protease dimerisation. 
The library consisted of 49 single modifications of the parent compound in the four 
marked different positions. 
Figure 5. General structure of the library designed to interfere with the Paxillin/α4 
interaction. The positions marked as X, Y and Z were substituded by ten different 
aromatic amino acids. 
 
 
 
 
 
